2024-11-14 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc. is a leading pharmaceutical company known for its innovative medicines and vaccines.

**1. Performance Comparison:**

* **Cumulative Return (MRK):** 93.88%
* **Cumulative Return (VOO):** 179.47%
* **Return Difference:** -85.59%
* **Relative Divergence:** 1.67 (This indicates that MRK's performance is currently in the 1.67th percentile of its historical range relative to VOO)

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 8.2% | 17.4% | -30.2% | 0.9 | 135.8 |
| 2016-2018  | 59.7% | 17.1% | 27.4% | 0.7 | 184.4 |
| 2017-2019  | 65.0% | 17.1% | 13.3% | 0.7 | 219.5 |
| 2018-2020  | 58.9% | 26.7% | 11.6% | 0.7 | 197.4 |
| 2019-2021  | 16.7% | 26.7% | -83.3% | 0.6 | 193.9 |
| 2020-2022  | 39.4% | 26.7% | 15.8% | 0.5 | 280.7 |
| 2021-2023  | 55.2% | 19.9% | 20.2% | 0.3 | 275.8 |
| 2022-2024  | 38.6% | 24.6% | 8.1% | 0.3 | 249.4 |

* **Analysis:** MRK has shown a history of outperformance in some years, with positive alpha values, indicating it generated returns beyond what would be expected given its beta. However, recent years have seen a decline in alpha, suggesting a less pronounced outperformance compared to the broader market.

**2. Recent Price Movement:**

* **Closing Price:** 98.5
* **5-day Moving Average:** 100.38
* **20-day Moving Average:** 103.54
* **60-day Moving Average:** 110.64

* **Analysis:** The stock is currently trading below all three moving averages, suggesting potential downward momentum. The stock has been declining in recent periods.

**3. Technical Indicators:**

* **RSI:** 24.48
* **PPO:** -0.21
* **Delta_Previous_Relative_Divergence (20 days):** -23.14 (This indicates a short-term downtrend)
* **Expected Return:** 0.0% (The expected return is 0% for long-term investment, suggesting potential for long-term growth but not necessarily outperforming the S&P 500)

**4. Recent Earnings and Outlook:**

| Date        | EPS | Revenue |
|-------------|-----|---------|
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2024-11-06 | 1.87 | 15.96 B$ |

* **Analysis:** Recent earnings have been mixed. The most recent earnings report (2024-11-06) missed analysts' expectations, contributing to the recent price decline. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |

* **Analysis:** MRK has shown consistent revenue growth and high profitability margins in recent quarters, highlighting its strong financial performance.

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |

* **Analysis:** ROE (Return on Equity) has shown some volatility. The recent quarter's negative ROE is a concern, indicating a potential for decreased profitability. 

**6. News and Recent Issues:**

* **Recent Earnings Release:** The recent earnings release from November 6th, 2024, missed analysts' estimates, leading to a drop in the stock price. 
* **Analyst Opinions:**  Analyst opinions on MRK are mixed.  FINBOLD reports a moderate buy rating with an average target price of $110.
* **Market Outlook:** The market outlook for MRK is uncertain. The stock is facing challenges from recent earnings misses and increased competition in the pharmaceutical industry. 

**7. Comprehensive Analysis:**

MRK is a large pharmaceutical company with a history of strong financial performance,  but recent performance has been below expectations.  The stock is currently trading below its moving averages, signaling a potential downtrend. The recent earnings miss and the market's reaction to it indicate a need for further analysis.  
Despite these challenges, MRK possesses strong fundamentals, including high profitability margins and consistent revenue growth.  The company's long-term prospects are largely contingent on its ability to address the recent concerns and deliver on its growth initiatives. 

**8. Conclusion:**

MRK is a stock with a mixed outlook. While the fundamentals remain strong, recent price action and earnings performance suggest caution. Investors should carefully consider the current market conditions and the company's ability to overcome its recent challenges before making an investment decision.  Long-term investors may find it an attractive investment due to its solid fundamentals and potential for growth. 
